OBIZUR

PreclinicalBiologic

Takeda

OBIZUR is one of 7 biologic programs targeting Acquired Hemophilia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acquired HemophiliaActive, not recruiting

Acquired HemophiliaPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Acquired Hemophilia

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

1 2

Rituxan

Pfizer

Phase 3

1 3

Hemlibra

Roche

Phase 2

2 4

Rituxan

Roche

Phase 2

1 5

Velcade

SShilpa Grover, MD, MPH

Phase 2

1 6

OBI-1

BBaxalta now part of Shire

Phase 3

2 7

OBIZUR

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Recruiting

Acquired Hemophilia

NCT06550882

Clinical

Trials by Indication[1]

Acquired Hemophilia2 trials

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

Recruiting· Takeda logo

Takeda··NCT06550882·9 enrolled

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Completed·BBaxalta now part of Shire··NCT02610127·53 enrolled

Effectiveness1 trial

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Completed·BBaxalta now part of Shire··NCT03199794·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for OBIZUR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OBIZUR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OBIZUR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Takeda

OBIZUR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Acquired Hemophilia2 trials

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News